Thiogenesis Therapeutics Statistics

Total Valuation

Thiogenesis Therapeutics has a market cap or net worth of CAD 25.03 million. The enterprise value is 20.88 million.

Market Cap	25.03M
Enterprise Value	20.88M

Important Dates

The next estimated earnings date is Monday, April 28, 2025.

Earnings Date	Apr 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Thiogenesis Therapeutics has 45.51 million shares outstanding. The number of shares has increased by 17.08% in one year.

Current Share Class	n/a
Shares Outstanding	45.51M
Shares Change (YoY)	+17.08%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	22.35%
Owned by Institutions (%)	n/a
Float	35.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	6.03
P/TBV Ratio	6.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.11
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 40.16

Current Ratio	40.16
Quick Ratio	39.85
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -108.88% and return on invested capital (ROIC) is -73.01%.

Return on Equity (ROE)	-108.88%
Return on Assets (ROA)	-69.09%
Return on Capital (ROIC)	-73.01%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.20% in the last 52 weeks. The beta is 0.69, so Thiogenesis Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-38.20%
50-Day Moving Average	0.61
200-Day Moving Average	0.68
Relative Strength Index (RSI)	36.34
Average Volume (20 Days)	7,593

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.39M
Pretax Income	-4.09M
Net Income	-4.09M
EBITDA	n/a
EBIT	-4.39M
Earnings Per Share (EPS)	-0.09

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	4.15M
Total Debt	n/a
Net Cash	4.15M
Net Cash Per Share	0.09
Equity (Book Value)	4.15M
Book Value Per Share	0.09
Working Capital	4.15M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-4.08M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Thiogenesis Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.08%
Shareholder Yield	-17.08%
Earnings Yield	-16.94%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a